Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism

Blood (2018) 132 (Supplement 1): 2527.

https://doi.org/10.1182/blood-2018-99-113589

Published: 2018

Journal Articles

Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study

Davendra P. S. Sohal, MD MPH, Nicole M. Kuderer, MD, Frances A. Shepherd, MD FRCPC, Ingrid Pabinger, Prof, Giancarlo Agnelli, MD, Howard A. Liebman, MA, MD, Eric Vicaut, MD, Guy Meyer, MD, Gary H. Lyman, MD MPH, Alok A. Khorana, MD

Blood (2016) 128 (22): 1422.

https://doi.org/10.1182/blood.V128.22.1422.1422

Published: 2016

Journal Articles

Global Prospective Cohort Study of Factors Associated with Venous Thromboembolism in Patients with Lung Cancer Receiving Cancer Therapy

Nicole M. Kuderer, MD, Marek S. Poniewierski, MD MS, MS, Eva Culakova, PhD MS, Gary H. Lyman, MD MPH, Alok A. Khorana, MD, Ingrid Pabinger, Prof, Giancarlo Agnelli, MD, Howard A. Liebman, MA, MD, Eric Vicaut, MD, Guy Meyer, MD, Frances A. Shepherd, MD FRCPC

Blood (2016) 128 (22): 3590.

https://doi.org/10.1182/blood.V128.22.3590.3590

Published: 2016

Journal Articles

Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data

Alexander Cohen, MD, Alexander S. Gallus, MD, Giancarlo Agnelli, MD, Harry R Buller, MD PhD, Raphael Pak, PhD, Anthony R. Porcari, PhD PharmD, Gary E. Raskob, PhD, Jeffrey I. Weitz, MDFRCPC, Takaharu Yamabe, PhD

Blood (2014) 124 (21): 1543.

https://doi.org/10.1182/blood.V124.21.1543.1543

Published: 2014

Journal Articles

Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism

Giancarlo Agnelli, MD, Harry Roger Buller, MD, PhD, Alexander Cohen, MD, Madelyn Curto, DVM, Alexander S. Gallus, M.D., Margot R. Johnson, MD, BSC, Anthony R. Porcari, PhD, PharmD, Gary E Raskob, PhD, Jeffrey I. Weitz, MD

Blood (2012) 120 (21): LBA-1.

https://doi.org/10.1182/blood.V120.21.LBA-1.LBA-1

Published: 2012

Journal Articles

Independent Risk Factors of Catheter-Related Thrombosis (CRT) in Adult Cancer Patients: An Individual Patient-Level Data (IPD) Meta-Analysis of Randomized Clinical Trials and Prospective Cohort Studies

Wael Saber, MD, MS, Teng Moua, MD, Eliot C. Williams, MD, PhD, Melina Verso, MD, Giancarlo Agnelli, MD, Stephen Couban, MD, Annie Young, RN, Marcello De Cicco, MD, Roberto Biffi, MD, Cornelis J. van Rooden, MD, Menno V. Huisman, MD, PhD, Daniele Fagnani, MD, Claudio Cimminiello, MD, Marco Moia, MD, Stephen P. Povoski, MD, Sharp Malak, MD, MPH, Agnes Y. Lee, MD, MSc, FRCPC

Blood (2008) 112 (11): 3814.

https://doi.org/10.1182/blood.V112.11.3814.3814

Published: 2008

Journal Articles

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein Thrombosis (DVT).

Wolfgang Mueck, PhD, Giancarlo Agnelli, MD, Harry Buller, MD

Blood (2007) 110 (11): 1880.

https://doi.org/10.1182/blood.V110.11.1880.1880

Published: 2007

Journal Articles

Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.

Bengt I. Eriksson, MD, PhD, Alexander G.G. Turpie, MD, PhD, Michael R. Lassen, MD, PhD, Martin H. Prins, MD, PhD, Giancarlo Agnelli, MD, PhD, Peter Kälebo, MD, PhD, Graham Wetherill, MSc, Lambertus Meems, MSc.

Blood (2007) 110 (11): 309.

https://doi.org/10.1182/blood.V110.11.309.309

Published: 2007

Journal Articles

Once- or Twice-Daily Rivaroxaban for the Treatment of Proximal Deep Vein Thrombosis: Similar Efficacy and Safety to Standard Therapy in Dose-Ranging Studies.

Harry R. Büller, MD, Giancarlo Agnelli, MD, the EINSTEIN-DVT ODIXa-DVT Study Groups

Blood (2006) 108 (11): 572.

https://doi.org/10.1182/blood.V108.11.572.572

Published: 2006

Journal Articles

YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study.

Bengt I. Eriksson, MD, Alexander G.G. Turpie, MD, Michael R. Lassen, MD, Martin H. Prins, MD, Giancarlo Agnelli, MD, Marleen L. Gaillard, PhD, Bert Meems, MSc

Blood (2005) 106 (11): 1865.

https://doi.org/10.1182/blood.V106.11.1865.1865

Published: 2005

Journal Articles

A Phase II Study of the Safety and Efficacy of a Novel Oral fXa Inhibitor (LY517717) for the Prevention of Venous Thromboembolism Following TKR or THR.

Giancarlo Agnelli, MD, Sylvia K. Haas, MD, Kathryn A. Krueger, MD, Alun W. Bedding, B.Sc, John T. Brandt, MD

Blood (2005) 106 (11): 278.

https://doi.org/10.1182/blood.V106.11.278.278

Published: 2005

Journal Articles

Incidence of Recurrent Venous Thromboembolism According to Duration of Vitamin K Antagonists: Results of a Meta-Analysis on Individual Data.

Florent Boutitie, PhD, Laurent Pinede, MD, Sam Schulman, MD, Giancarlo Agnelli, MD, Gary Rascob, MD, Jim Jullian, MD, Jack Hirsh, MD, Clive Kearon, MD

Blood (2004) 104 (11): 710.

https://doi.org/10.1182/blood.V104.11.710.710

Published: 2004

NARROW

Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism

Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study

Global Prospective Cohort Study of Factors Associated with Venous Thromboembolism in Patients with Lung Cancer Receiving Cancer Therapy

Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data

Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism

Independent Risk Factors of Catheter-Related Thrombosis (CRT) in Adult Cancer Patients: An Individual Patient-Level Data (IPD) Meta-Analysis of Randomized Clinical Trials and Prospective Cohort Studies

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein Thrombosis (DVT).

Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.

Once- or Twice-Daily Rivaroxaban for the Treatment of Proximal Deep Vein Thrombosis: Similar Efficacy and Safety to Standard Therapy in Dose-Ranging Studies.

YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study.

A Phase II Study of the Safety and Efficacy of a Novel Oral fXa Inhibitor (LY517717) for the Prevention of Venous Thromboembolism Following TKR or THR.

Incidence of Recurrent Venous Thromboembolism According to Duration of Vitamin K Antagonists: Results of a Meta-Analysis on Individual Data.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only